The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Selinexor combination regimens reduce toxicity
The current dosing and schedule of selinexor for the treatment of multiple myeloma is challenging for patients. Here, Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, explains how different combination regimens are meaning that the dose of selinexor can be lowered, leading to a reduced GI toxicity and the ability to keep patients on the agent for longer. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
